Where Taysha Gene Therapies Stands With Analysts
Portfolio Pulse from Benzinga Insights
14 analysts have provided mixed opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, with a majority being bullish or somewhat bullish. The average 12-month price target has increased to $6.79. Despite a decline in revenue and challenges in ROE and ROA, the company maintains a strong market position with a significant market capitalization.
July 23, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have mixed opinions on Taysha Gene Therapies, with a majority being bullish or somewhat bullish. The average 12-month price target has increased to $6.79. Despite a decline in revenue and challenges in ROE and ROA, the company maintains a strong market position.
The majority of analysts are bullish or somewhat bullish on TSHA, and the average price target has increased, indicating positive sentiment. However, the company faces challenges in revenue, ROE, and ROA, which may temper the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100